熱門資訊> 正文

BRIEF-Travere Therapeutics Provides Corporate Update And 2025 Outlook

2025-01-13 21:39

Jan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2025 OUTLOOK
SNDA FOR MODIFICATION OF LIVER MONITORING FOR FILSPARI IN IGAN ACCEPTED FOR FDA REVIEW ; PDUFA TARGET ACTION DATE OF AUG 28
ON TRACK TO PROVIDE REGULATORY UPDATE ON SPARSENTAN IN FSGS BY ITS Q4 2024 EARNINGS CALL
EXPECTS FISCAL YEAR 2024 NET PRODUCT SALES TO BE APPROXIMATELY $227 MILLION

Source text: ID:nGNX4n2d4x

Further company coverage: TVTX.O

((Reuters.Briefs@thomsonreuters.com;))

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。